- US Capitol Capsule: Innovation without high drug prices: A difficult conversation
- AbbVie, Gilead, Janssen dazzle with Hep C data
- Janssen gains FDA nod for HCV protease inhibitor Olysio
- Merck data shake up all-oral hepatitis C race
ANALYSIS Other Informa Analysis
- Interview: building on Spiriva – Boehringer Ingelheim's Allan Hillgrove
- INTERVIEW: Dr Reddy's CEO on the 'windshield and rear view mirror'